Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback

Juliana M. Kling, N. Maritza Dowling, Heather A. Bimonte-Nelson, Carey E. Gleason, Kejal Kantarci, Jo Ann E. Manson, Hugh S. Taylor, Eliot A. Brinton, Rogerio A. Lobo, Marcelle I. Cedars, Lubna Pal, Genevieve Neal-Perry, Frederick Naftolin, S. Mitchell Harman, Virginia M. Miller

Research output: Contribution to journalArticle

Abstract

Changes in pituitary-ovarian hormones across the menopausal transition have multiple physiological consequences. However, little is known about how the major types of postmenopausal hormone therapy (HT) affect pituitary-ovarian hormonal relationships. This study evaluated these relationships in recently menopausal women (52.45 ± 2.49 yr of age) in the Kronos Early Estrogen Prevention Study (KEEPS) who were compliant to randomized, double-blinded treatment with oral conjugated equine estrogen (o-CEE; n = 109), transdermal 17β-estradiol (t-E2; n = 107), or placebo (n = 146). Androstenedione, testosterone, 17β-estradiol, estrone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured in serum before (baseline) and 48 mo after randomization to treatment. Descriptive summaries of hormone levels were performed, and multiple regression analyses were used to examine the effects of o-CEE, t-E2, and placebo on these hormone levels at 48 mo, adjusting for baseline levels. A network analysis examined the covariance of changes in hormone levels over the 48 mo within treatment groups. As expected, at 48 mo of treatment, hormone levels differed between women in the two active treatment groups compared with placebo, and network analysis indicated stronger relationships among hormone levels in the t-E2 and o-CEE groups compared with placebo. Associations among testosterone, 17β-estradiol, FSH, and LH differed between the o-CEE group compared with t-E2 and placebo groups. Thus, two common HT regimens differentially alter pituitary-ovarian hormone levels, altering feedback cycles and interhormonal associations in recently menopausal women. These interactions provide the basis for future studies investigating the impact of hormonal modulation of aging, including cognitive decline in women.

Original languageEnglish (US)
Pages (from-to)R912-R920
JournalAmerican journal of physiology. Regulatory, integrative and comparative physiology
Volume317
Issue number6
DOIs
StatePublished - Dec 1 2019

Fingerprint

Hormones
Placebos
Estradiol
Pituitary Hormones
Follicle Stimulating Hormone
Luteinizing Hormone
Therapeutics
Testosterone
Conjugated (USP) Estrogens
Androstenedione
Estrone
Random Allocation
Estrogens
Regression Analysis
Serum

Keywords

  • androgen
  • estrogen
  • follicle-stimulating hormone
  • hormone therapy
  • menopause
  • pituitary-ovarian hormones

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. / Kling, Juliana M.; Dowling, N. Maritza; Bimonte-Nelson, Heather A.; Gleason, Carey E.; Kantarci, Kejal; Manson, Jo Ann E.; Taylor, Hugh S.; Brinton, Eliot A.; Lobo, Rogerio A.; Cedars, Marcelle I.; Pal, Lubna; Neal-Perry, Genevieve; Naftolin, Frederick; Harman, S. Mitchell; Miller, Virginia M.

In: American journal of physiology. Regulatory, integrative and comparative physiology, Vol. 317, No. 6, 01.12.2019, p. R912-R920.

Research output: Contribution to journalArticle

Kling, JM, Dowling, NM, Bimonte-Nelson, HA, Gleason, CE, Kantarci, K, Manson, JAE, Taylor, HS, Brinton, EA, Lobo, RA, Cedars, MI, Pal, L, Neal-Perry, G, Naftolin, F, Harman, SM & Miller, VM 2019, 'Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback', American journal of physiology. Regulatory, integrative and comparative physiology, vol. 317, no. 6, pp. R912-R920. https://doi.org/10.1152/ajpregu.00234.2019
Kling, Juliana M. ; Dowling, N. Maritza ; Bimonte-Nelson, Heather A. ; Gleason, Carey E. ; Kantarci, Kejal ; Manson, Jo Ann E. ; Taylor, Hugh S. ; Brinton, Eliot A. ; Lobo, Rogerio A. ; Cedars, Marcelle I. ; Pal, Lubna ; Neal-Perry, Genevieve ; Naftolin, Frederick ; Harman, S. Mitchell ; Miller, Virginia M. / Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. In: American journal of physiology. Regulatory, integrative and comparative physiology. 2019 ; Vol. 317, No. 6. pp. R912-R920.
@article{b26b9339fa274666a562857d53e54a61,
title = "Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback",
abstract = "Changes in pituitary-ovarian hormones across the menopausal transition have multiple physiological consequences. However, little is known about how the major types of postmenopausal hormone therapy (HT) affect pituitary-ovarian hormonal relationships. This study evaluated these relationships in recently menopausal women (52.45 ± 2.49 yr of age) in the Kronos Early Estrogen Prevention Study (KEEPS) who were compliant to randomized, double-blinded treatment with oral conjugated equine estrogen (o-CEE; n = 109), transdermal 17β-estradiol (t-E2; n = 107), or placebo (n = 146). Androstenedione, testosterone, 17β-estradiol, estrone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured in serum before (baseline) and 48 mo after randomization to treatment. Descriptive summaries of hormone levels were performed, and multiple regression analyses were used to examine the effects of o-CEE, t-E2, and placebo on these hormone levels at 48 mo, adjusting for baseline levels. A network analysis examined the covariance of changes in hormone levels over the 48 mo within treatment groups. As expected, at 48 mo of treatment, hormone levels differed between women in the two active treatment groups compared with placebo, and network analysis indicated stronger relationships among hormone levels in the t-E2 and o-CEE groups compared with placebo. Associations among testosterone, 17β-estradiol, FSH, and LH differed between the o-CEE group compared with t-E2 and placebo groups. Thus, two common HT regimens differentially alter pituitary-ovarian hormone levels, altering feedback cycles and interhormonal associations in recently menopausal women. These interactions provide the basis for future studies investigating the impact of hormonal modulation of aging, including cognitive decline in women.",
keywords = "androgen, estrogen, follicle-stimulating hormone, hormone therapy, menopause, pituitary-ovarian hormones",
author = "Kling, {Juliana M.} and Dowling, {N. Maritza} and Bimonte-Nelson, {Heather A.} and Gleason, {Carey E.} and Kejal Kantarci and Manson, {Jo Ann E.} and Taylor, {Hugh S.} and Brinton, {Eliot A.} and Lobo, {Rogerio A.} and Cedars, {Marcelle I.} and Lubna Pal and Genevieve Neal-Perry and Frederick Naftolin and Harman, {S. Mitchell} and Miller, {Virginia M.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1152/ajpregu.00234.2019",
language = "English (US)",
volume = "317",
pages = "R912--R920",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback

AU - Kling, Juliana M.

AU - Dowling, N. Maritza

AU - Bimonte-Nelson, Heather A.

AU - Gleason, Carey E.

AU - Kantarci, Kejal

AU - Manson, Jo Ann E.

AU - Taylor, Hugh S.

AU - Brinton, Eliot A.

AU - Lobo, Rogerio A.

AU - Cedars, Marcelle I.

AU - Pal, Lubna

AU - Neal-Perry, Genevieve

AU - Naftolin, Frederick

AU - Harman, S. Mitchell

AU - Miller, Virginia M.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Changes in pituitary-ovarian hormones across the menopausal transition have multiple physiological consequences. However, little is known about how the major types of postmenopausal hormone therapy (HT) affect pituitary-ovarian hormonal relationships. This study evaluated these relationships in recently menopausal women (52.45 ± 2.49 yr of age) in the Kronos Early Estrogen Prevention Study (KEEPS) who were compliant to randomized, double-blinded treatment with oral conjugated equine estrogen (o-CEE; n = 109), transdermal 17β-estradiol (t-E2; n = 107), or placebo (n = 146). Androstenedione, testosterone, 17β-estradiol, estrone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured in serum before (baseline) and 48 mo after randomization to treatment. Descriptive summaries of hormone levels were performed, and multiple regression analyses were used to examine the effects of o-CEE, t-E2, and placebo on these hormone levels at 48 mo, adjusting for baseline levels. A network analysis examined the covariance of changes in hormone levels over the 48 mo within treatment groups. As expected, at 48 mo of treatment, hormone levels differed between women in the two active treatment groups compared with placebo, and network analysis indicated stronger relationships among hormone levels in the t-E2 and o-CEE groups compared with placebo. Associations among testosterone, 17β-estradiol, FSH, and LH differed between the o-CEE group compared with t-E2 and placebo groups. Thus, two common HT regimens differentially alter pituitary-ovarian hormone levels, altering feedback cycles and interhormonal associations in recently menopausal women. These interactions provide the basis for future studies investigating the impact of hormonal modulation of aging, including cognitive decline in women.

AB - Changes in pituitary-ovarian hormones across the menopausal transition have multiple physiological consequences. However, little is known about how the major types of postmenopausal hormone therapy (HT) affect pituitary-ovarian hormonal relationships. This study evaluated these relationships in recently menopausal women (52.45 ± 2.49 yr of age) in the Kronos Early Estrogen Prevention Study (KEEPS) who were compliant to randomized, double-blinded treatment with oral conjugated equine estrogen (o-CEE; n = 109), transdermal 17β-estradiol (t-E2; n = 107), or placebo (n = 146). Androstenedione, testosterone, 17β-estradiol, estrone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured in serum before (baseline) and 48 mo after randomization to treatment. Descriptive summaries of hormone levels were performed, and multiple regression analyses were used to examine the effects of o-CEE, t-E2, and placebo on these hormone levels at 48 mo, adjusting for baseline levels. A network analysis examined the covariance of changes in hormone levels over the 48 mo within treatment groups. As expected, at 48 mo of treatment, hormone levels differed between women in the two active treatment groups compared with placebo, and network analysis indicated stronger relationships among hormone levels in the t-E2 and o-CEE groups compared with placebo. Associations among testosterone, 17β-estradiol, FSH, and LH differed between the o-CEE group compared with t-E2 and placebo groups. Thus, two common HT regimens differentially alter pituitary-ovarian hormone levels, altering feedback cycles and interhormonal associations in recently menopausal women. These interactions provide the basis for future studies investigating the impact of hormonal modulation of aging, including cognitive decline in women.

KW - androgen

KW - estrogen

KW - follicle-stimulating hormone

KW - hormone therapy

KW - menopause

KW - pituitary-ovarian hormones

UR - http://www.scopus.com/inward/record.url?scp=85076330788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076330788&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.00234.2019

DO - 10.1152/ajpregu.00234.2019

M3 - Article

C2 - 31663769

AN - SCOPUS:85076330788

VL - 317

SP - R912-R920

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 6

ER -